Patent application number | Description | Published |
20080206254 | Novel Anti-Factor VIII Antibodies - The present invention relates to new antibodies and fragments and derivatives thereof, which are particularly suited for the characterization of the structure and function of Factor VIII (FVIII) of the coagulation pathway, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament The invention also relates to cell lines producing the specific antibodies. The present invention furthermore relates to pharmaceutical compositions comprising the antibodies, fragments and/or derivatives of the Invention and to methods of preventing and treating cardiovascular disorders by using the antibodies or fragments and derivatives thereof or pharmaceutical compositions thereof. | 08-28-2008 |
20100266586 | VARIABLE ANTIBODIES - The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures. | 10-21-2010 |
20100272715 | VARIABLE ANTIBODIES - The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures. | 10-28-2010 |
20100303866 | IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS - The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides. | 12-02-2010 |
20100322967 | B CELL TOLERANCE INDUCTION - The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor. | 12-23-2010 |
20100330088 | STRATEGIES TO PREVENT AND/OR TREAT IMMUNIE RESPONSES TO SOLUBLE ALLOFACTORS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a soluble allofactor and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore. | 12-30-2010 |
20110002903 | IMMUNOGENIC CONTROL OF TUMOURS AND TUMOUR CELLS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C—(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments therefore. | 01-06-2011 |
20110010786 | TRANSGENIC ANIMAL EXPRESSING B CELL ANTIGEN RECEPTOR - The invention relates to a non-human transgenic mammal containing in its genome a DNA construct expressing a B cell antigen receptor specific for factor VIII of the coagulation pathway. | 01-13-2011 |
20110111395 | CD4+CELLS WITH CYTOLYTIC PROPERTIES - The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them. | 05-12-2011 |
20120009678 | IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore. | 01-12-2012 |
20130259885 | IMMUNOGENIC PEPTIDES FOR USE IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, IMMUNE RESPONSES TO ALLOFACTORS, ALLERGIC DISEASES, TUMORS, GRAFT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENE THERAPY OR GENE VACCINATION - The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination. | 10-03-2013 |
20130280284 | MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS - The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases. | 10-24-2013 |
20130302375 | MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS - The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination. | 11-14-2013 |
20140186297 | CD4+ T-CELLS WITH CYTOLYTIC PROPERTIES - The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them. | 07-03-2014 |
20140370044 | MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES - The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells. | 12-18-2014 |
20140377299 | IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore. | 12-25-2014 |
20150087593 | COAGULATION FACTOR VIII WITH REDUCED IMMUNOGENICITY - The invention describes factor VIII molecules with reduced capacity to elicit activation of NKT cells for use in the treatment of congenital and/or acquired haemophilia A and in bleeding disorders. Said factor VIII molecule is obtainable by:
| 03-26-2015 |